BridgeBio Pharma, Inc. — Director's Dealing 2022

Jan 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-29

Reporting Person: Lo Andrew (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-29	Common Stock	P	6000	$12.90	Acquired	46599	Direct
2021-12-30	Common Stock	P	1500	$14.30	Acquired	48099	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	205583	Indirect